Lymphoma & Myeloma Clinical Trials
Last Updated: 10/26/2023
CAR T/Cellular Therapy
Lymphoma CAR T/Cellular Therapy
Previously Untreated
2020-0872 A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
2022-0463 An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma
Previously Treated
2023-0706 A phase 1b multicenter, open-label, study of JNJ-90009530, an autologous anti-CD20 CAR-T cell therapy in adult participants with relapsed or refractory B-cell Non-Hodgkin lymphoma
2023-0639 Long-term follow-up study for participants previously treated with Ciltacabtagene Autoleucel
2023-0485 An open-label, multicenter phase 2 study Evaluating the Efficacy and Safety of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants with Relapsed/Refractory Large B-Cell Lymphoma after CD19-directed CAR T-cell Therapy
2023-0202 A Phase 1 multicenter study evaluating the safety and efficacy of ACE1831, an Allogeneic CD20-Conjugated Gamma Delta T-Cell therapy, In adult subjects with relapsed/refractory CD20-expressing B-Cell malignancies
2020-0660 Expanded access protocol (eap) for patients receiving lisocabtagene maraleucel that is nonconforming for commercial release
2021-0543 Evaluating the Feasibility Of a Digital Health Coaching for Individuals Following CAR T Therapy
2020-1136 A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy, in Subjects With Relapsed and/or Refractory B-cell Lymphoma
2020-1263 Long-term Follow-up Protocol for Subjects Treated with Adicet Bio Allogeneic Gamma Delta T-cell Investigational Products
2020-1137 (CD20): A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta (?d) T Cells in Adults with B Cell Malignancies, in Monotherapy and Combination with IL-2
2020-1041 (ANTLER): A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ANTLER)
2019-1250 A Phase 2, Open-label, ingle-arm, Multi Cohort, Multi Center Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects with Relapsed or Refractory Indolent B-Cell Non-Hdgkin Lymphoma (NHL)
2022-0661 A phase Ib, open-label, multicenter, single arm study evaluating the preliminary efficacy, safety, and pharmacokinetics of Glofitamab in combination with Rituximab plus Ifosfamide, Carboplatin Etoposide Phosphate in patients with relapsed/ refractory transplant or CAR-T therapy eligible diffuse B-Cell Lymphoma
2022-0846 A phase 2/3, randomized, double blind, placebo-controlled, multicenter study of NKTR-255 vs placebo following CD19-directed CAR-T cell therapy in patients with relapsed/refractory large B-cell lymphoma
2023-0176 A pilot study for pupillary assessment to predict CAR-T related neurotoxicity
2022-0938 A phase 1 study of JV-213 autologous CD79b-targeting chimeric antigen receptor T-cell therapy in adults with relapsed or refractory B-cell lymphomas
2023-0025 A phase 1 study evaluating SC291, a hypoimmune allogeneic CD19-directed CAR T cell therapy, in relapsed and/or refractory B-cell malignancies (ARDENT)
Myeloma CAR T/Cell Therapy
Previously Treated
2021-0543 Evaluating the Feasibility Of a Digital Health Coaching for Individuals Following CAR T Therapy
2023-0115 A phase 1, multicenter, open-label study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in patients with relapsed/refractory multiple Myeloma (CaMMouflage Trial)
Lymphoma Clinical Trials
2021-1003 A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies
Non Hodgkins Lymphoma
Indolent Lymphoma (Follicular, Marginal Zone, Small Lymphocytic Leukemia)
Previously Untreated
2023-0063 Phase 2 trial of Obinutuzumab and CC-99282 for patients with previously untreated high tumor burden follicular lymphoma
Previously Treated
2023-0610 Phase 1, open-label study of Autologous SIRPa-low Macrophages (sirpant-m) administered by intratumoral injection alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory Non-Hodgkin's Lymphoma.
2023-0613 A phase 1/2a, open-label, dose escalation trial of GEN3017 with expansion cohorts in relapsed or refractory CD30+ classical Hodgkin lymphoma and CD30+ non-Hodgkin lymphoma
2021-1214 A Phase 1/2, First in Human, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Triple-specific T-cell Engager 1A46 in Adult Patients with Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies
2021-1001 A phase Ib, multi-center, open-label dose escalation and expansion platform study of VAY736 as single agent and in combination with select antineoplastic agents in patients with non-Hodgkin Lymphoma (NHL)
2012-1107(2010-0837LYMPHOMA)A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study
2022-0394 A Phase lb, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, And Efficacy OfMosunetuzumab Or Glofitamab In Combination With CC-220 And CC-99282 In Patients With B-Cell Non-Hodgkin Lymphoma
2022-0298 A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma
2022-0206 A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, PK/PD, and Clinical Activity of Intravenously Administered KT-413 in Adult Patients With Relapsed or Refractory B-cell NHL
2021-0647 An Open-Label, Multicenter, Phase 2 Study of CLR131 in Patients with Relapsed or Refractory (R/R)Select B-Cell Malignancies (CLOVER-1) andExpansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM)
2021-0583 A Phase 2, Open-label, Mul30ticenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
2021-0454 A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination with Ublituximab in Subjects with B-Cell Lymphoma or Chronic Lymphocytic Leukemia
2021-0226 A Phase I/II Open Label, Single Center, Study of the Combination of ALX148, Rituximab and Lenalidomide in Patients with Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
2021-0091 A Multicenter, Phase1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-cell Non Hodkins Lymphoma
2020-0272 A phase 1B/3 double-blind, randomized, active-contrlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractor follicular lymphoma
2020-0034 (aR2): A Phase II Study of Acalabrutinib, Lenalidomide and Rituximab (aR2) in Patients with Previously Untreated High Tumor Burden Follicular Lymphoma
2018-1160 (CC-99282): A Phase I, Multi-Center, Open Label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Rituximab in Subjects with Relapsed or Refractory Non-Hodgkins Lymphoma
2017-0475 (UC-961): A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies
2017-0224 (Ibrutinib): Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
2021-0499 Phase III, Randomized, Open-label, multicenter study evaluating efficacy and safety of mosunetuzumab in combination with lenalidomide in comparison to rituximab in combination with lenalidomide in patients with follicular lymphoma after at least one line
2022-0551 A phase 1/2, open-label study of Valemetostat in combination with Rituximab and Lenalidomide in relapsed or refractory Follicular Lymphoma
2023-0335 A phase 3 randomized, open-label, multicenter study of Zanubrutinib (BGB-3111) plus anti-CD20 antibodies versus Lenalidomide Plus Rituximab in patients with Relapsed/Refractory follicular or marginal zone lymphoma
2022-0459 A phase II trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in patients with relapsed B-cell NHL
2022-0916 A phase 1, first-in-human study of JNJ-80948543, a T-cell redirecting antibody, in participants with NHL and CLL
Aggressive Lymphoma (Large B cell Lymphoma, Diffuse Large B cell Lymphoma, Burkitt's Lymphoma)
Newly diagnosed
2021-0046 Smart Stop: A Phase II trial of Rituximab,Lenalidomide, Acalabrutinib, Tafasitamab prior to andwith standard chemotherapy for patients with newly diagnosed DLBCL
2020-0686 A Phase II Study to Determine the Response Kinetics, Safety and Efficacy of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-cell Lymphoma
2023-0031 Phase 2 trial of Epcoritamab in combination with Rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell Lymphoma.
Previously Treated
2023-0673 A phase 2 Study of Axicabtagene Ciloleucel and Glofitamab as second-line therapy for relapsed or refractory, or high-risk untreated patients with large B Cell Lymphoma
2023-0610 Phase 1, open-label study of Autologous SIRPa-low Macrophages (sirpant-m) administered by intratumoral injection alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory Non-Hodgkin's Lymphoma.
2023-0485 An open-label, multicenter phase 2 study Evaluating the Efficacy and Safety of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants with Relapsed/Refractory Large B-Cell Lymphoma after CD19-directed CAR T-cell Therapy
2021-1214 A Phase 1/2, First in Human, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Triple-specific T-cell Engager 1A46 in Adult Patients with Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies
2021-1169 REAL-MIND: Prospective multicenter observational study of patients with relapsed or refractory diffuse large B-cell lymphoma starting second- or third-line therapy and not receiving autologous stem cell transplant
2021-1001 A phase Ib, multi-center, open-label dose escalation and expansion platform study of VAY736 as single agent and in combination with select antineoplastic agents in patients with non-Hodgkin Lymphoma (NHL)
2022-0147 A Phase II Study ofLoncastuximab Tesirine as Consolidation Strategy in Patients with Large B-cell Lymphoma who Achieve Partial Remission After CAR T-cell Therapy
PA15-0957 DNA Sequencing-Based Monitoring of MinimalResidual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
2021-0647 An Open-Label, Multicenter, Phase 2 Study of CLR131 in Patients with Relapsed or Refractory (R/R)Select B-Cell Malignancies (CLOVER-1) andExpansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM)
2020-0184 A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
2021-0181 A Multicenter Phase 2 Study of Belantamab mafodotin in Relapsed or Refractory Plasmablastic Lymphoma and ALK+ Large B-cell Lymphoma
2021-0463 An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
2021-0263 A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
2018-1160 (CC-99282): A Phase I, Multi-Center, Open Label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Rituximab in Subjects with Relapsed or Refractory Non-Hodgkins Lymphoma
2021-0915 A Phase 1/1b, Open-label Multi-center Two-part Study of SETD2 Inhibitor EZM0414 in Subjects with Relapsed/refractory Multiple Myeloma and Relapsed/refractory Diffuse Large B Cell Lymphoma
2022-0602 An open-label, phase I study to evaluate the safety, pharmacokinetics and preliminary anti-tumor activity of RO7227166 (a CD19 targeted 4-1BB ligand) in combination with Obinutuzumab and in combination with Glofitmab following a pre-treatment dose of Obinutuzumab administered in participants with relapsed/refractory B-Cell non-Hodgkin's lymphoma
2023-0274 A randomized, open-label, multicenter phase III study evaluating efficacy and safety of Mosunetuzumab in combination with Polatuzumab Vedotin in comparison with Rituximab in combination with Gemcitabine plus Oxaliplatin in participants with relapsed or refractory aggressive B-cell
non-Hodgkin's Lymphoma.
2022-1031 Phase 1/2 multi-center study to evaluate the safety and efficacy of Onct-808 in adult subjects with relapsed or refractory aggressive B-cell malignancies
2023-0079 Allogeneic natural killer T-Cells expressing CD19 specific chimeric antigen receptor and interleukin-15 in relapsed or refractory B-Cell malignancies 2 (ANCHOR2)
Mantle Cell Lymphoma
Previously Untreated
2023-0412 A Multicentre, Phase II, Randomised, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination with Venetoclax and Rituximab in Participants with Treatment-Naive Mantle Cell Lymphoma (TrAVeRse)
2020-0872 A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
Previously Treated
2023-0695 Tafasitamab, Lenalidomide and Venetoclax combination therapy for relapsed or refractory Mantle Cell Lymphoma (V-MIND)
2023-0610 Phase 1, open-label study of Autologous SIRPa-low Macrophages (sirpant-m) administered by intratumoral injection alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory Non-Hodgkin's Lymphoma.
2021-1108 Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
2021-0647 An Open-Label, Multicenter, Phase 2 Study of CLR131 in Patients with Relapsed or Refractory (R/R)Select B-Cell Malignancies (CLOVER-1) andExpansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM)
2020-1242 A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor inPatients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
2019-0421 (ACAL): A Phase II Study of Acalabrutinib in Ibrutinib-Intolerant Mantle Cell Lymphoma
2019-1022 (Match): A Pilot Study of Interrogating biological Signaling Pathways Dysregulations and in vitro Screening with Personalized Therapies in resistant Mantle Cell Lymphoma (MCL) - the MCL Match Trial
2018-0935 (Venetoclax & Acalabrutinib): An open label, Phase II investigator initiated study of venetoclax and acalabrutinib in previously treated relapsed/refractory patients with mantle cell lymphoma (MCL)
2017-0475 (UC-961): A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies
2022-0722 A single-Arm, open-label, multicenter phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of Bcl-2 inhibitor BGB-11417 in patients with relapsed or refractory Mantle Cell Lymphoma
2022-0724 A phase 3, randomized, double-blind, placebo-controlled, multicenter study of Zilovertamab (an ROR1 Antibody) plus Ibrutinib versus Ibrutinib plus placebo in subjects with relapsed or refractory Mantle Cell Lymphoma
Hodgkin Lymphoma
Newly Diagnosed
Previously Treated
2023-0613 A phase 1/2a, open-label, dose escalation trial of GEN3017 with expansion cohorts in relapsed or refractory CD30+ classical Hodgkin lymphoma and CD30+ non-Hodgkin lymphoma
2021-1033 An open-label, multi-center, non-randomized phase I dose escalation study to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 given as monotherapy in patients with relapsed or refractory T-cell Lymphoma
2021-1130 A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an anti-PD-1 and anti-TIM-3 Bispecific Antibody, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
T-Cell Lymphoma
Newly Diagnosed
2021-0058 A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects with Peripheral T-cell Lymphoma (PTCL) with less than 10% CD30 Expression
2021-0148 A Multi-center Phase Ib Trial Evaluating the Safety and Efficacy of Lacutamab in Patients with Relapsed Peripheral T-cell Lymphoma that Express KIR3DL2
Previously Treated
2022-0235 A Single-arm, Phase II Study to Evaluate the Efficacy and Safety ofLinperlisib (YY-20394) Monotherapy in Patients with Relapsed or Refractory Peripheral T/NK. Cell Lymphoma
2021-0388 A Phase I/II, Open-Label, Multicentre Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-toumor Activity AZD4205 in Patients with Peripheral T Cell Lymphoma (PTCL)
2018-1064 (TTI-622): A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advance Relapsed or Refractory Lymphoma or Myeloma
2021-1033 An open-label, multi-center, non-randomized phase I dose escalation study to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 given as monotherapy in patients with relapsed or refractory T-cell Lymphoma
2022-0643 A phase 1/2, open-label, first-in-human, multiple ascending dose multicenter study of MT-101 in subjects with CD5+ relapsed/ refractory T Cell Lymphoma
2022-0698 A phase 1-2, open-label study of the safety, pharmacokinetics, pharmacodynamics, and preliminary activity of Tolinapant in combination with Oral Decitabine/Cedazuridine and oral Decitabine/Cedazuridine alone in subjects with relapsed/refractory peripheral t-cell lymphoma.
Multiple Myeloma Clinical Trials
Newly Diagnosed
2023-0617 SWOG S2209: A phase III randomized trial for newly diagnosed Multiple Myeloma (NDMM) patients considered frail or in a subset of "intermediate fit" comparing upfront three-drug induction regimens followed by double- or single-agent maintenance.
2022-0417 SMOLDERING MYELOMA REGISTRATION TRIAL (SMRT STUDY)
2021-0442 Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide,and Dexamethasone vs Carfilzomib, Lenalidomide,and Dexamethasone vs Bortezomib, Lenalidomide,and Dexamethasone in Patients with Newly-Diagnosed Multiple Myeloma (ADVANCE)
2021-0191 (DETER-SMM) EAA173: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
2020-0431 A Phase 1 with Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
2023-0322 A phase 3, two-stage, randomized, multi-center, controlled, open-label study comparing Iberdomide maintenance to Lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM) (EXCALIBER-Maintenance)
2023-0363 Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in previously untreated patients with symptomatic multiple Myeloma (Linker-MM4 Study)
Previously Treated
NCI10076: A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of AMG 232 in Combination with Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
2023-0719 A phase 3, two-stage,randomized, multicenter, open-label study comparing Mezigdomide(CC-92480), Bortezomib and Dexamethasone (MeziVd)versus Pomalidomide,Bortezomib and Dexamethasone (PVD) in subjects with Relapsed or RefractoryMultiple myeloma (RRMM): successor-1
2023-0687 An open-label, randomized, phase 3 study of Linvoseltamab (REGN5458; anti-BCMA x anti-CD3 Bispecific Antibody) versus the combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in patients with relapsed/refractory multiple myeloma (LINKER-MM3)
2023-0199 SPIND: Compassionate use of Belantamab Mafodotin for Relapsed and Refractory Multiple Myeloma
2023-0527 Phase I/II open label study of Belumosudil Mesylate alone, and in combination with Dexamethasone, in patients with relapsed/refractory multiple myeloma
2023-0453 A phase 1b/2 dose escalation and expansion study of the combination of the bispecific T cell redirection antibodies Talquetamab and Teclistamab in participants with relapsed or refractory multiple myeloma
NCI10076 A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of AMG 232 in Combination with Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
2021-0185 A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients with Plasma Cell Disorders Including Multiple Myeloma
2020-1229 A Phase 3 randomized, open label, multicenter study ofisatuximab (SAR650984) in combination withlenalidomide and dexamethasone versus lenalidomideand dexamethasone in patients with high-risk smoldering multiple myeloma
2020-0973 Expanded Access Protocol (EAP) for Subjectsreceiving Idecabtagene Vicleucel that is Nonconforming for Commercial release
2016-0172 Quality of Life in Patients with Asymptomatic Monoclonal Gammopathies
2021-0647 An Open-Label, Multicenter, Phase 2 Study of CLR131 in Patients with Relapsed or Refractory (R/R)Select B-Cell Malignancies (CLOVER-1) andExpansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM)
2020-1124 Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody)nin Patients with Relapsed or Refractory Multiple Myeloma
2020-0464 (CAEL-101): Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amylo
2020-0720 A Non-Interventional, Multinational, Observational Study with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
2020-0534 (APG-2575):A Phase Ib /II Study of Safety, Tolerability and Efficacy of APG-2575 Alone or in Combination with Other Therapeutic Agents in Patients with Waldenstrom Macroglobulinemia (WM)
2020-0103 (BFCR4350A):An Open-Label, Multicenter, Phase I Trial Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of BFCR4350A In Patients With Relapsed Or Refractory Multiple Myeloma
2019-0452 (RRMM): A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination with Standard Treatments in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)
2019-0499 (CT053): Open label, multi-center, phase 1b clinical trial to evaluate the safety and efficacy of autologous CAR-BCMA T cells (CT053) in patients with relapsed and/or refractory multiple myeloma
2018-0512 (D+B-Dex in R/R MM): A Phase 2 Study of Daratumumab, Bortezomab and Dexamethasone followed by Daratumumab, Ixaazomib, and Dexamethasone for Relapsed/Refractory Myeloma
2018-0192 (XmAb13676): A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 in Patients with CD20-Expressing Hematologic Malignancies
2021-0915 A Phase 1/1b, Open-label Multi-center Two-part Study of SETD2 Inhibitor EZM0414 in Subjects with Relapsed/refractory Multiple Myeloma and Relapsed/refractory Diffuse Large B Cell Lymphoma
2022-0598 A phase II study of CART-ddBCMA for the treatment of patients with relapsed or refractory multiple myeloma.
2022-0993 International Myeloma foundation study of the outcomes of patients with relapsed or high-risk Myeloma receiving Novel Immunotherapies
2023-0115 A phase 1, multicenter, open-label study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in patients with relapsed/refractory multiple Myeloma (CaMMouflage Trial)
2023-0188 Phase 1b clinical study of fully human BCMA chimeric antigen receptor autologous t cell injection (ct103a) in the treatment of patients with relapsed/refractory multiple myeloma
2023-0195, 2023-0197, 2023-0199 SPIND: Compassionate use of Belantamab Mafodotin for relapsed and refractory multiple myeloma
2023-0252 A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (TalD) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy
Other Clinical Trials
2023-0581 A randomized trial of fecal microbiota transplantation for remedying antibiotics-induced microbiota dysbiosis in lymphoma patients receiving Axicabtagene Ciloleucel therapy
2022-0224 The impact of molecular heterogeneity on response to targeted and cellular therapies in T and NK cell lymphoma
2022-0358 Real-World Outcomes in Patients with Relapsed or Refractory (R/R) Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)
2021-0393 Analysis of apheresis and infusion product retains from lymphoma patients treated with standard of care axicabtagene ciloleucel
2005-0656 A Collection of Blood and Tissue Samples from Patients with Lymphoma and/or Myeloma and Normal Donors
PA12-1098 Repository of Biological Samples and Data for Pediatric Patients
PA15-0172 Late-effects and Health Concerns in Long-term Childhood Cancer Survivors
PA16-0163 Predictors of late outcomes and quality of life in lymphoma survivors
2022-0784 Myeloma Genetics and Epidemiology - Genetica y Epidemiologia de Mieloma (GEM Study)
2022-0533 Disparities among Childhood and Adolescent/Young Adult (AYA) Cancer Populations
PA15-0575 Observational prospective Research study In monoclonal Gammopathies leadINg to myeloma (ORIGIN study)
2021-1088 A Multicenter, Open-label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma with or without HIV
2021-0758 Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
2021-0626 Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
2022-0396 Feasibility of Combined Genomics/Transcriptomics for Patients with Lymphoma
2022-0437 A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy ofDR-01 in Adult Subjects with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
2021-0696 A Phase 2, Open-label Study to Evaluate the Safety andEfficacy of MK-7684A (MK-7684 [Vibostolimab] withMK-3475 [Pembrolizumab] Coformulation) inParticipants with Relapsed or Refractory Hematological Malignancies2021
2020-0238 A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Adult Subjects With R/R T or B Cell Malignancies
2020-1172 Use of tocilizumab for the clinical management of by CAR-T cell therapy-induced CRS
2021-0392 Collection of blood samples from normal donors
2021-0440 A Collection of Blood and Tissue Samples from Patients with Amyloidosis and/or Monoclonal Gammopathies (including Lymphoplasmacytic
Lymphoma) and Normal Donors
2021-0816 A Study to Evaluate Long-Term Safety of CAR-T Cell Therapy in Patients with Hematologic Malignancies
2022-0052 A Prospective Study Of Conventional Bone Marrow Biopsies And Bone Marrow Biopsies Performed Through An Indwelling Bone Marrow Port, Using A Modified PROMIS Pain Intensity Scale For Pain Assessment
2022-0167 Precision Approaches to Treat Mantle Cell Lymphoma: Integrating Multi-omics Based Models
2022-0193 Outcomes of Cutaneous T-Cell Lymphoma Patients on Mogamulizumab
PA14-0094 The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Protocol
PA19-0436 MOLECULAR MONITORING OF MYELOMA RESPONSE AND RESISTANCE MECHANISMS
RCR04-0567 RETROSPECTIVE CHART REVIEW OF ERDHEIM-CHESTER DISEASE PATIENTS TREATED WITH INTERFERON-ALPHA TO DETERMINE THE CLINICAL RESPONSE AND OUTCOME
PCR06-0459 Database of Patients with Plasma Cell Dyscrasias
PA18-1062 Discovering new biomarkers to detect circulating tumor genomic material in patients with B-cell Lymphoma
PA18-1073 Pilot study of the Validation of a Single Cell Proteogenomic Assay in Plasma Cell Dyscrasias and Its Precursor Disease
2021-0049 HSP70 as a target for New drugs in Multiple Myeloma and Lymphoma
2023-0218 Pilot study to assess the feasibility, cost-effectiveness, and patient-reported outcomes of outpatient CAR T-cell administration for patients with Multiple Myeloma
2023-0253 Intermediate-size population expanded access program (EAP) for ciltacabtagene autoleucel (cilta-cel) out-of-specification (OOS) in patients with multiple myeloma
2022-0492 PET adapted Brentuximab Vedotin and Pembrolizumab in combination with Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
2022-0603 Feasibility and clinical utility of cell-free DNA (cfDNA) in identifying actionable alterations and minimal residual disease for lymphoma patients across community centers in Texas.
2023-0183 Single patient IND: Expanded access of Ruxolitinib to treat a single patient for hemophagocytic lymphohistiocytosis associated with peripheral T-Cell lymphoma
2023-0329 An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL)
2022-0497 A phase 1b open-label study to evaluate the safety and tolerability of intravenous Modakafusp Alfa as part of combination therapy in adult patients
2022-0918 Expanded access study for the treatment of patients with commercially out-of-specification Axicabtagene Ciloleucel
2023-0420 Phase 1/2 study of IDP 023 as a single agent and in combination with antibody therapies in patients with advanced Hematologic cancers.
2020-0797 Mechanisms of Late-effects in Childhood and AYA Cancer Survivors
2023-0677 ASH research collaborative data hub protocol: A multi-center data hub of individuals living with Hematologic disease.